25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

IRWD (Ironwood Pharmaceuticals Inc) Stock Analysis
Buy, Hold or Sell?

Let's analyze Ironwood Pharmaceuticals Inc together

I guess you are interested in Ironwood Pharmaceuticals Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • πŸ“Š Fundamental Analysis (FA) – Ironwood Pharmaceuticals Inc’s Financial Insights
  • πŸ“ˆ Technical Analysis (TA) – Ironwood Pharmaceuticals Inc’s Price Targets

I'm going to help you getting a better view of Ironwood Pharmaceuticals Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Ironwood Pharmaceuticals Inc

I send you an email if I find something interesting about Ironwood Pharmaceuticals Inc.

1. Quick Overview

1.1. Quick analysis of Ironwood Pharmaceuticals Inc (30 sec.)










1.2. What can you expect buying and holding a share of Ironwood Pharmaceuticals Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$-1.90
Expected worth in 1 year
$-1.81
How sure are you?
60.0%

+ What do you gain per year?

Total Gains per Share
$0.08
Return On Investment
4.3%

For what price can you sell your share?

Current Price per Share
$1.92
Expected price per share
$1.26 - $3.369
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Ironwood Pharmaceuticals Inc (5 min.)




Live pricePrice per Share (EOD)
$1.92
Intrinsic Value Per Share
$-17.05 - $8.38
Total Value Per Share
$-18.94 - $6.48

2.2. Growth of Ironwood Pharmaceuticals Inc (5 min.)




Is Ironwood Pharmaceuticals Inc growing?

Current yearPrevious yearGrowGrow %
How rich?-$308.1m-$331m$17.3m5.5%

How much money is Ironwood Pharmaceuticals Inc making?

Current yearPrevious yearGrowGrow %
Making money-$1.9m$2.3m-$4.2m-216.8%
Net Profit Margin-14.2%1.5%--

How much money comes from the company's main activities?

2.3. Financial Health of Ironwood Pharmaceuticals Inc (5 min.)




3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Ironwood Pharmaceuticals Inc?

Welcome investor! Ironwood Pharmaceuticals Inc's management wants to use your money to grow the business. In return you get a share of Ironwood Pharmaceuticals Inc.

First you should know what it really means to hold a share of Ironwood Pharmaceuticals Inc. And how you can make/lose money.

Speculation

The Price per Share of Ironwood Pharmaceuticals Inc is $1.92. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Ironwood Pharmaceuticals Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Ironwood Pharmaceuticals Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $-1.90. Based on the TTM, the Book Value Change Per Share is $0.02 per quarter. Based on the YOY, the Book Value Change Per Share is $0.04 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Ironwood Pharmaceuticals Inc.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps0.157.6%-0.01-0.6%0.010.6%-0.48-25.0%-0.08-4.3%-0.12-6.1%
Usd Book Value Change Per Share0.168.3%0.021.1%0.042.0%-0.40-20.7%-0.08-4.3%-0.07-3.6%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.168.3%0.021.1%0.042.0%-0.40-20.7%-0.08-4.3%-0.07-3.6%
Usd Price Per Share0.72-2.69-9.08-7.58-9.21-11.45-
Price to Earnings Ratio1.24-31.32--197.72--52.84--27.45--14.55-
Price-to-Total Gains Ratio4.52-33.39-51.33-37.34-36.71-37.79-
Price to Book Ratio-0.38--1.41--4.62--1.63-14.68-23.24-
Price-to-Total Gains Ratio4.52-33.39-51.33-37.34-36.71-37.79-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.92
Number of shares520
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.02-0.08
Usd Total Gains Per Share0.02-0.08
Gains per Quarter (520 shares)10.86-43.43
Gains per Year (520 shares)43.43-173.71
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1043330-174-184
2087760-347-358
301301190-521-532
401741620-695-706
502172050-869-880
602612480-1042-1054
703042910-1216-1228
803473340-1390-1402
903913770-1563-1576
1004344200-1737-1750

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share3.01.00.075.0%7.05.00.058.3%15.05.00.075.0%21.019.00.052.5%22.045.01.032.4%
Book Value Change Per Share3.01.00.075.0%9.03.00.075.0%16.04.00.080.0%24.016.00.060.0%32.034.02.047.1%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.040.00.0%0.00.068.00.0%
Total Gains per Share3.01.00.075.0%9.03.00.075.0%16.04.00.080.0%24.016.00.060.0%32.034.02.047.1%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Ironwood Pharmaceuticals Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.1590.021+663%0.039+313%-0.398+350%-0.084+152%-0.069+143%
Book Value Per Share---1.897-1.931+2%-1.972+4%-0.603-68%0.489-488%0.130-1564%
Current Ratio--0.8253.119-74%1.622-49%9.392-91%10.458-92%7.858-90%
Debt To Asset Ratio--1.8991.894+0%1.731+10%1.442+32%1.119+70%1.126+69%
Debt To Equity Ratio----0%-0%0.173-100%5.072-100%9.330-100%
Dividend Per Share----0%-0%-0%-0%-0%
Enterprise Value---441303426.400-135706110.950-69%851866644.275-152%884380133.042-150%1317313600.998-134%1607642755.988-127%
Eps--0.145-0.012+108%0.011+1210%-0.480+430%-0.083+157%-0.117+181%
Ev To Ebitda Ratio---2.3650.534-543%8.310-128%4.918-148%6.464-137%-29.322+1140%
Ev To Sales Ratio---1.294-0.654-49%2.121-161%2.002-165%3.118-142%4.882-127%
Free Cash Flow Per Share---0.0930.046-301%0.219-142%0.209-144%0.271-134%0.090-203%
Free Cash Flow To Equity Per Share---0.092-0.018-80%-0.060-35%0.303-130%0.262-135%0.094-198%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--8.379----------
Intrinsic Value_10Y_min---17.045----------
Intrinsic Value_1Y_max--0.837----------
Intrinsic Value_1Y_min--0.009----------
Intrinsic Value_3Y_max--2.517----------
Intrinsic Value_3Y_min---1.460----------
Intrinsic Value_5Y_max--4.199----------
Intrinsic Value_5Y_min---4.547----------
Market Cap311873529.600+63%116952573.600436135639.050-73%1532969644.275-92%1314510883.042-91%1580544800.998-93%1902570155.988-94%
Net Profit Margin--0.277-0.142+151%0.015+1723%-0.753+372%-0.123+144%-0.275+199%
Operating Margin--0.5420.129+319%0.283+91%-0.530+198%-0.103+119%-0.179+133%
Operating Ratio--0.4710.724-35%0.561-16%1.434-67%1.075-56%1.199-61%
Pb Ratio-1.012-167%-0.380-1.408+271%-4.616+1116%-1.629+329%14.678-103%23.236-102%
Pe Ratio3.304+63%1.23931.318-96%-197.716+16058%-52.836+4365%-27.446+2315%-14.550+1274%
Price Per Share1.920+63%0.7202.685-73%9.075-92%7.579-91%9.211-92%11.453-94%
Price To Free Cash Flow Ratio-5.174-167%-1.9407.458-126%10.681-118%8.767-122%8.534-123%-22.208+1045%
Price To Total Gains Ratio12.046+63%4.51733.394-86%51.328-91%37.340-88%36.709-88%37.787-88%
Quick Ratio--0.7702.892-73%1.500-49%9.179-92%10.221-92%8.125-91%
Return On Assets--0.069-0.007+111%0.004+1703%-0.137+299%-0.044+164%-0.044+164%
Return On Equity----0%-0%0.019-100%0.409-100%-0.0810%
Total Gains Per Share--0.1590.021+663%0.039+313%-0.398+350%-0.084+152%-0.069+143%
Usd Book Value---308162000.000-313721000.000+2%-331054750.000+7%-81298916.667-74%97571150.000-416%30133750.000-1123%
Usd Book Value Change Per Share--0.1590.021+663%0.039+313%-0.398+350%-0.084+152%-0.069+143%
Usd Book Value Per Share---1.897-1.931+2%-1.972+4%-0.603-68%0.489-488%0.130-1564%
Usd Dividend Per Share----0%-0%-0%-0%-0%
Usd Enterprise Value---441303426.400-135706110.950-69%851866644.275-152%884380133.042-150%1317313600.998-134%1607642755.988-127%
Usd Eps--0.145-0.012+108%0.011+1210%-0.480+430%-0.083+157%-0.117+181%
Usd Free Cash Flow---15070000.0007484000.000-301%36589250.000-141%36637416.667-141%46589400.000-132%15937175.000-195%
Usd Free Cash Flow Per Share---0.0930.046-301%0.219-142%0.209-144%0.271-134%0.090-203%
Usd Free Cash Flow To Equity Per Share---0.092-0.018-80%-0.060-35%0.303-130%0.262-135%0.094-198%
Usd Market Cap311873529.600+63%116952573.600436135639.050-73%1532969644.275-92%1314510883.042-91%1580544800.998-93%1902570155.988-94%
Usd Price Per Share1.920+63%0.7202.685-73%9.075-92%7.579-91%9.211-92%11.453-94%
Usd Profit--23599000.000-1971250.000+108%2303000.000+925%-76330166.667+423%-11700300.000+150%-18159800.000+177%
Usd Revenue--85239000.00077129750.000+11%100141250.000-15%94696916.667-10%98251200.000-13%89364075.000-5%
Usd Total Gains Per Share--0.1590.021+663%0.039+313%-0.398+350%-0.084+152%-0.069+143%
 EOD+6 -2MRQTTM+18 -17YOY+16 -193Y+14 -235Y+15 -2210Y+15 -21

3.3 Fundamental Score

Let's check the fundamental score of Ironwood Pharmaceuticals Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-153.304
Price to Book Ratio (EOD)Between0-1-1.012
Net Profit Margin (MRQ)Greater than00.277
Operating Margin (MRQ)Greater than00.542
Quick Ratio (MRQ)Greater than10.770
Current Ratio (MRQ)Greater than10.825
Debt to Asset Ratio (MRQ)Less than11.899
Debt to Equity Ratio (MRQ)Less than10.000
Return on Equity (MRQ)Greater than0.150.000
Return on Assets (MRQ)Greater than0.050.069
Total5/10 (50.0%)

3.4 Technical Score

Let's check the technical score of Ironwood Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5061.401
Ma 20Greater thanMa 501.669
Ma 50Greater thanMa 1001.486
Ma 100Greater thanMa 2001.179
OpenGreater thanClose2.060
Total4/5 (80.0%)

4. In-depth Analysis

4.1 About Ironwood Pharmaceuticals Inc

Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well as for pediatric patients suffering from functional constipation under the LINZESS and CONSTELLA names. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and Apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 for short bowel syndrome patients dependent on parenteral support, as well as for acute graft versus host disease. It has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.

Fundamental data was last updated by Penke on 2025-11-07 20:08:05.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating less efficient.
The company is efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is unable to pay all its debts by selling its assets.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is overpriced.
Based on how much money comes from the company's main activities, the company is cheap.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profitΒ Ironwood Pharmaceuticals Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compareΒ Ironwood Pharmaceuticals Inc to theΒ Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of 27.7%Β means thatΒ $0.28 for each $1Β in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Ironwood Pharmaceuticals Inc:

  • The MRQ is 27.7%. The company is making a huge profit. +2
  • The TTM is -14.2%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ27.7%TTM-14.2%+41.9%
TTM-14.2%YOY1.5%-15.7%
TTM-14.2%5Y-12.3%-1.9%
5Y-12.3%10Y-27.5%+15.2%
4.3.1.2. Return on Assets

Shows howΒ efficientΒ Ironwood Pharmaceuticals Inc is using its assets to generate profit.

  • Above 5% is considered healthyΒ but always compareΒ Ironwood Pharmaceuticals Inc to theΒ Drug Manufacturers - Specialty & Generic industry mean.
  • 6.9% Return on Assets means thatΒ Ironwood Pharmaceuticals Inc generatedΒ $0.07 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Ironwood Pharmaceuticals Inc:

  • The MRQ is 6.9%. Using its assets, the company is efficient in making profit. +1
  • The TTM is -0.7%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ6.9%TTM-0.7%+7.6%
TTM-0.7%YOY0.4%-1.1%
TTM-0.7%5Y-4.4%+3.7%
5Y-4.4%10Y-4.4%+0.0%
4.3.1.3. Return on Equity

Shows how efficient Ironwood Pharmaceuticals Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compareΒ Ironwood Pharmaceuticals Inc to theΒ Drug Manufacturers - Specialty & Generic industry mean.
  • 0.0% Return on Equity means Ironwood Pharmaceuticals Inc generated $0.00Β for eachΒ $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Ironwood Pharmaceuticals Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y40.9%-40.9%
5Y40.9%10Y-8.1%+49.0%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Ironwood Pharmaceuticals Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

MeasuresΒ how efficient Ironwood Pharmaceuticals Inc is operatingΒ .

  • Measures how much profit Ironwood Pharmaceuticals Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compareΒ Ironwood Pharmaceuticals Inc to theΒ Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of 54.2%Β means the company generated $0.54 Β for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Ironwood Pharmaceuticals Inc:

  • The MRQ is 54.2%. The company is operating very efficient. +2
  • The TTM is 12.9%. The company is operating less efficient.
Trends
Current periodCompared to+/- 
MRQ54.2%TTM12.9%+41.3%
TTM12.9%YOY28.3%-15.4%
TTM12.9%5Y-10.3%+23.3%
5Y-10.3%10Y-17.9%+7.6%
4.3.2.2. Operating Ratio

Measures how efficient Ironwood Pharmaceuticals Inc is keepingΒ operating costsΒ low.

  • Below 1 is considered healthy (always compare toΒ Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 0.47 means that the operating costs are $0.47 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Ironwood Pharmaceuticals Inc:

  • The MRQ is 0.471. The company is very efficient in keeping operating costs low. +2
  • The TTM is 0.724. The company is efficient in keeping operating costs low. +1
Trends
Current periodCompared to+/- 
MRQ0.471TTM0.724-0.253
TTM0.724YOY0.561+0.163
TTM0.7245Y1.075-0.351
5Y1.07510Y1.199-0.124
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Ironwood Pharmaceuticals Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Ironwood Pharmaceuticals Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare toΒ Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 0.82Β means the company has $0.82 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Ironwood Pharmaceuticals Inc:

  • The MRQ is 0.825. The company is just not able to pay all its short-term debts. -1
  • The TTM is 3.119. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ0.825TTM3.119-2.294
TTM3.119YOY1.622+1.497
TTM3.1195Y10.458-7.340
5Y10.45810Y7.858+2.600
4.4.3.2. Quick Ratio

Measures if Ironwood Pharmaceuticals Inc is able to pay off Short-term Debt but only usingΒ theΒ most liquid assets.

  • Above 1 is considered healthy butΒ always compareΒ Ironwood Pharmaceuticals Inc to theΒ Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 0.77Β means the company can pay off $0.77 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Ironwood Pharmaceuticals Inc:

  • The MRQ is 0.770. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 2.892. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ0.770TTM2.892-2.122
TTM2.892YOY1.500+1.392
TTM2.8925Y10.221-7.329
5Y10.22110Y8.125+2.095
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Ironwood Pharmaceuticals Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much %Β of Ironwood Pharmaceuticals IncΒ assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compareΒ Ironwood Pharmaceuticals Inc to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 1.90Β means that Ironwood Pharmaceuticals Inc assets areΒ financed with 189.9% credit (debt) and the remaining percentage (100% - 189.9%)Β is financed by its owners/shareholders.Β 

Let's take a look of the Debt to Asset Ratio trends of Ironwood Pharmaceuticals Inc:

  • The MRQ is 1.899. The company is unable to pay all its debts by selling its assets. -2
  • The TTM is 1.894. The company is unable to pay all its debts by selling its assets. -2
Trends
Current periodCompared to+/- 
MRQ1.899TTM1.894+0.004
TTM1.894YOY1.731+0.164
TTM1.8945Y1.119+0.775
5Y1.11910Y1.126-0.007
4.5.4.2. Debt to Equity Ratio

Measures ifΒ Ironwood Pharmaceuticals Inc is able toΒ pay off its debts by usingΒ shareholders equity.

  • Below 2 is considered healthy butΒ always compareΒ Ironwood Pharmaceuticals Inc to theΒ Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 0.0% means that company has $0.00 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Ironwood Pharmaceuticals Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y5.072-5.072
5Y5.07210Y9.330-4.258
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

MeasuresΒ how much money you payΒ for each share forΒ every $1 in earnings Ironwood Pharmaceuticals Inc generates.

  • Above 15 is considered overpriced butΒ always compareΒ Ironwood Pharmaceuticals Inc to theΒ Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of 1.24 means the investor is paying $1.24Β for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Ironwood Pharmaceuticals Inc:

  • The EOD is 3.304. Based on the earnings, the company is cheap. +2
  • The MRQ is 1.239. Based on the earnings, the company is cheap. +2
  • The TTM is 31.318. Based on the earnings, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD3.304MRQ1.239+2.065
MRQ1.239TTM31.318-30.079
TTM31.318YOY-197.716+229.034
TTM31.3185Y-27.446+58.764
5Y-27.44610Y-14.550-12.896
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Ironwood Pharmaceuticals Inc:

  • The EOD is -5.174. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -1.940. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is 7.458. Based on how much money comes from the company's main activities, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD-5.174MRQ-1.940-3.234
MRQ-1.940TTM7.458-9.398
TTM7.458YOY10.681-3.223
TTM7.4585Y8.534-1.076
5Y8.53410Y-22.208+30.742
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price ofΒ Ironwood Pharmaceuticals Inc is to cheap or to expensiveΒ compared to its book value.

  • At or below 1 is considered healthyΒ (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A PB ratio of -0.38 means the investor is paying $-0.38Β for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Ironwood Pharmaceuticals Inc:

  • The EOD is -1.012. Based on the equity, the company is expensive. -2
  • The MRQ is -0.380. Based on the equity, the company is expensive. -2
  • The TTM is -1.408. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.012MRQ-0.380-0.633
MRQ-0.380TTM-1.408+1.028
TTM-1.408YOY-4.616+3.208
TTM-1.4085Y14.678-16.086
5Y14.67810Y23.236-8.558
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Ironwood Pharmaceuticals Inc.

4.8.1. Institutions holding Ironwood Pharmaceuticals Inc

Institutions are holding 97.135% of the shares of Ironwood Pharmaceuticals Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-06-30Vanguard Group Inc9.97460.0002162021295059683.2235
2025-06-30Armistice Capital, LLC9.94250.199916150000245000017.8832
2025-06-30Sarissa Capital Management LP9.80057.395215919435-470565-2.871
2025-06-30BlackRock Inc7.40180.0002120229981440741.2129
2025-06-30Renaissance Technologies Corp5.17510.0088406169-1534323-15.4351
2025-06-30AQR Capital Management LLC3.79580.003761656373641762144.2925
2025-06-30Kynam Capital Management, LP3.36560.42215466825-356113-6.1157
2025-06-30Marshall Wace Asset Management Ltd2.45860.003239935573436036616.3061
2025-06-30Charles Schwab Investment Management Inc2.25590.00053664276101726138.4305
2025-06-30Geode Capital Management, LLC2.15430.00023499332812432.3769
2025-06-30Two Sigma Advisers, LLC2.08340.0053384100149950079.566
2025-06-30Bank of America Corp2.06720.000233578721929356135.0602
2025-06-30Qube Research & Technologies2.0630.00243351002439431.3288
2025-06-30State Street Corp1.91320.00013107719-390570-11.1646
2025-06-30Two Sigma Investments LLC1.69330.003527505731523377124.1348
2025-06-30LSV Asset Management1.69310.00462750200-1247601-31.2072
2025-06-30Connor Clark & Lunn Inv Mgmt Ltd1.35870.0056220694871890448.312
2025-06-30Federated Hermes Inc1.34030.0029217703887167666.7766
2025-06-30Jane Street Group LLC1.07440.00031745122-1764995-50.2831
2025-06-30D. E. Shaw & Co LP1.02790.0009166963915599151421.6716
Total 72.63928.0587117990571+13658848+11.6%

4.9.2. Funds holding Ironwood Pharmaceuticals Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-07-31Vanguard Total Stock Mkt Idx Inv2.52460.00024100846-90463-2.1583
2025-08-31iShares Russell 2000 ETF2.32420.0075377531800
2025-06-30Vanguard Strategic Equity Inv1.5060.0189244622800
2025-06-30Vanguard Explorer Inv1.37570.0079223459300
2025-08-30Schwab Fundamental U.S. Small CompanyETF1.33510.032216870086940.4025
2025-06-30Fidelity Small Cap Index0.98390.0045159827015357810.6305
2025-07-31Vanguard Institutional Extnd Mkt Idx Tr0.95230.00151546796-704831-31.3032
2025-07-31Xtrackers S&P 500 Swap ETF 1C0.88520.0105143780700
2025-06-30Federated Hermes MDT SCC Institutional0.79190.0668128634153766571.8154
2025-06-30Federated Hermes MDT Small Cap Core IS0.79190.0668128634153766571.8154
2025-08-31iShares Russell 2000 Growth ETF0.76350.0132124015600
2025-08-31iShares Biotechnology ETF0.58340.022894756600
2025-06-30Vanguard Strategic Small-Cap Equity Inv0.520.033884469200
2025-07-31Vanguard Russell 2000 ETF0.47290.0047768185-46348-5.6901
2025-07-31Fidelity Extended Market Index0.46910.0015761941-6268-0.8159
2025-06-30Federated Hermes MDT Small Cap Growth IS0.44850.110372844925972555.4111
2025-06-30Federated Hermes MDT SCG Institutional0.44850.110372844925972555.4111
2025-06-30Vanguard US Value Factor ETF0.41080.0795667325-183885-21.6028
2025-08-30Schwab US Small-Cap ETFβ„’0.40310.004665472616800.2573
2025-08-29Inspire Small/Mid Cap ETF0.34920.340656728500
Total 18.33980.937929790014+726937+2.4%

5.3. Insider Transactions

Insiders are holding 2.665% of the shares of Ironwood Pharmaceuticals Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2025-02-10Michael ShetzlineSELL412691.76
2025-02-10Ronald SilverSELL120481.76
2025-02-10Thomas A MccourtSELL1390641.76
2024-11-18Andrew DavisSELL53604.08
2024-11-18Sravan Kumar EmanySELL110014.08
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2024-06-302024-09-302024-12-312025-03-312025-06-30
Net Working Capital  132,670-3,449129,22114,301143,522-31,040112,482-153,254-40,772



5.2. Latest Balance Sheet

Balance Sheet of 2025-06-30. Currency in USD. All numbers in thousands.

Summary
Total Assets342,946
Total Liabilities651,108
Total Stockholder Equity-308,162
 As reported
Total Liabilities 651,108
Total Stockholder Equity+ -308,162
Total Assets = 342,946

Assets

Total Assets342,946
Total Current Assets191,753
Long-term Assets151,193
Total Current Assets
Cash And Cash Equivalents 92,852
Net Receivables 86,172
Other Current Assets 12,729
Total Current Assets  (as reported)191,753
Total Current Assets  (calculated)191,753
+/-0
Long-term Assets
Property Plant Equipment 14,130
Intangible Assets 2,453
Long-term Assets Other 5,151
Long-term Assets  (as reported)151,193
Long-term Assets  (calculated)21,734
+/- 129,459

Liabilities & Shareholders' Equity

Total Current Liabilities232,525
Long-term Liabilities418,583
Total Stockholder Equity-308,162
Total Current Liabilities
Short-term Debt 205,772
Short Long Term Debt 199,332
Accounts payable 1,389
Other Current Liabilities 25,364
Total Current Liabilities  (as reported)232,525
Total Current Liabilities  (calculated)431,857
+/- 199,332
Long-term Liabilities
Long term Debt 385,000
Capital Lease Obligations 14,337
Long-term Liabilities Other 22,466
Long-term Liabilities  (as reported)418,583
Long-term Liabilities  (calculated)421,803
+/- 3,220
Total Stockholder Equity
Common Stock162
Retained Earnings -1,711,522
Accumulated Other Comprehensive Income -2,026
Other Stockholders Equity 1,405,224
Total Stockholder Equity (as reported)-308,162
Total Stockholder Equity (calculated)-308,162
+/-0
Other
Capital Stock162
Cash and Short Term Investments 92,852
Common Stock Shares Outstanding 161,723
Liabilities and Stockholders Equity 342,946
Net Debt 505,817
Net Invested Capital 276,170
Net Working Capital -40,772
Property Plant and Equipment Gross 14,130
Short Long Term Debt Total 598,669



5.3. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2025-06-302025-03-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-312008-12-312007-12-31
> Total Assets 
135,908
140,723
0
0
158,847
162,451
338,130
322,084
304,500
301,365
272,024
249,727
219,480
208,977
249,176
208,663
246,518
229,907
325,093
384,031
325,843
278,962
418,871
371,064
346,168
333,513
305,528
653,941
613,426
619,121
603,325
700,208
731,978
709,821
701,319
705,079
625,086
605,674
571,095
618,218
416,652
332,050
363,538
315,721
334,343
402,748
404,005
443,538
492,324
559,238
599,344
1,007,218
1,079,371
1,126,927
1,083,381
975,690
1,040,344
1,100,519
1,155,277
603,220
524,063
471,073
438,819
395,620
389,519
350,908
327,213
342,946
342,946327,213350,908389,519395,620438,819471,073524,063603,2201,155,2771,100,5191,040,344975,6901,083,3811,126,9271,079,3711,007,218599,344559,238492,324443,538404,005402,748334,343315,721363,538332,050416,652618,218571,095605,674625,086705,079701,319709,821731,978700,208603,325619,121613,426653,941305,528333,513346,168371,064418,871278,962325,843384,031325,093229,907246,518208,663249,176208,977219,480249,727272,024301,365304,500322,084338,130162,451158,84700140,723135,908
   > Total Current Assets 
0
108,086
0
0
126,996
131,448
306,398
282,159
263,300
259,075
229,052
208,382
178,766
167,567
206,265
166,083
202,347
184,440
275,634
335,780
275,826
229,128
371,305
325,760
304,081
289,730
263,876
526,959
505,779
500,205
495,701
386,142
382,804
380,181
357,853
341,487
314,053
311,596
275,727
279,542
248,548
266,435
201,832
220,985
257,638
306,852
333,943
374,275
433,317
495,839
538,246
620,268
695,374
745,225
710,101
617,826
698,994
780,626
866,374
317,599
253,610
233,288
208,174
178,180
178,604
182,368
160,579
191,753
191,753160,579182,368178,604178,180208,174233,288253,610317,599866,374780,626698,994617,826710,101745,225695,374620,268538,246495,839433,317374,275333,943306,852257,638220,985201,832266,435248,548279,542275,727311,596314,053341,487357,853380,181382,804386,142495,701500,205505,779526,959263,876289,730304,081325,760371,305229,128275,826335,780275,634184,440202,347166,083206,265167,567178,766208,382229,052259,075263,300282,159306,398131,448126,99600108,0860
       Cash And Cash Equivalents 
62,427
67,722
0
0
96,269
123,145
76,338
35,384
58,700
44,321
46,214
48,185
68,820
87,282
131,612
87,083
125,867
136,700
105,302
219,461
144,452
75,490
205,129
95,357
51,269
74,297
63,692
256,450
248,077
261,287
280,926
277,332
182,937
54,004
133,319
182,132
162,640
125,736
144,788
145,415
141,562
173,172
119,045
98,908
139,231
177,023
231,143
253,252
307,555
362,564
438,469
492,699
574,276
620,129
593,371
504,365
574,188
656,203
740,342
175,321
110,164
92,154
121,540
105,524
88,211
88,559
108,481
92,852
92,852108,48188,55988,211105,524121,54092,154110,164175,321740,342656,203574,188504,365593,371620,129574,276492,699438,469362,564307,555253,252231,143177,023139,23198,908119,045173,172141,562145,415144,788125,736162,640182,132133,31954,004182,937277,332280,926261,287248,077256,45063,69274,29751,26995,357205,12975,490144,452219,461105,302136,700125,86787,083131,61287,28268,82048,18546,21444,32158,70035,38476,338123,14596,2690067,72262,427
       Short-term Investments 
29,509
22,045
0
0
17,659
0
222,230
236,221
192,100
203,706
174,355
152,912
106,309
76,734
70,496
70,570
67,456
31,528
136,727
81,077
97,938
122,112
127,140
206,621
213,692
174,037
152,173
236,865
214,229
178,107
153,526
48,041
136,936
251,212
162,020
90,763
62,777
95,680
49,659
35,831
19,836
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000000000019,83635,83149,65995,68062,77790,763162,020251,212136,93648,041153,526178,107214,229236,865152,173174,037213,692206,621127,140122,11297,93881,077136,72731,52867,45670,57070,49676,734106,309152,912174,355203,706192,100236,221222,230017,6590022,04529,509
       Net Receivables 
0
7,121
0
0
9,919
5,219
4,723
196
5,000
2,895
4,184
110
741
652
109
2,466
182
1,487
48
5,298
3,086
513
10,337
4,455
380
25,839
33,849
27,049
36,971
54,518
53,018
53,147
53,715
64,854
51,147
60,357
80,083
82,157
70,651
80,519
65,375
80,950
72,617
103,786
96,570
117,246
91,107
105,379
113,250
122,351
87,152
102,252
101,773
114,042
105,515
102,357
116,545
115,458
115,749
118,990
124,546
129,122
72,015
58,108
76,202
81,886
39,768
86,172
86,17239,76881,88676,20258,10872,015129,122124,546118,990115,749115,458116,545102,357105,515114,042101,773102,25287,152122,351113,250105,37991,107117,24696,570103,78672,61780,95065,37580,51970,65182,15780,08360,35751,14764,85453,71553,14753,01854,51836,97127,04933,84925,8393804,45510,3375133,0865,298481,4871822,4661096527411104,1842,8955,0001964,7235,2199,919007,1210
       Inventory 
0
2,498
0
0
0
0
-295,461
0
0
0
-216,270
0
0
0
-198,060
-151,689
965
6,699
19,704
20,379
20,561
22,145
23,413
12,989
13,045
4,954
4,950
0
0
0
0
0
0
1,081
1,513
0
479
735
1,705
1,099
76
0
593
1,735
2,298
648
0
0
0
0
0
0
0
0
0
0
0
1,250
1,250
788
788
0
0
0
0
0
0
0
00000007887881,2501,250000000000006482,2981,7355930761,0991,70573547901,5131,0810000004,9504,95413,04512,98923,41322,14520,56120,37919,7046,699965-151,689-198,060000-216,270000-295,46100002,4980
   > Long-term Assets 
0
32,637
0
0
31,851
31,003
31,732
39,925
41,200
42,290
42,972
41,345
40,714
41,410
42,911
42,580
44,171
45,467
49,459
48,251
50,017
49,834
47,566
45,304
42,087
43,783
41,652
126,982
107,647
118,916
107,624
314,066
349,174
329,640
343,466
363,592
311,033
294,078
295,368
338,676
168,104
65,615
161,706
94,736
76,705
95,896
70,062
69,263
59,007
63,399
61,098
386,950
383,997
381,702
373,280
357,864
341,350
319,893
288,903
285,621
270,453
237,785
230,645
217,440
210,915
168,540
166,634
151,193
151,193166,634168,540210,915217,440230,645237,785270,453285,621288,903319,893341,350357,864373,280381,702383,997386,95061,09863,39959,00769,26370,06295,89676,70594,736161,70665,615168,104338,676295,368294,078311,033363,592343,466329,640349,174314,066107,624118,916107,647126,98241,65243,78342,08745,30447,56649,83450,01748,25149,45945,46744,17142,58042,91141,41040,71441,34542,97242,29041,20039,92531,73231,00331,8510032,6370
       Property Plant Equipment 
4,146
24,596
0
0
23,403
22,551
23,540
29,117
33,300
34,369
35,074
33,484
32,875
33,625
35,140
34,859
36,470
37,537
36,100
35,013
37,231
37,376
35,524
33,560
30,415
29,826
27,477
25,017
23,183
21,075
19,446
17,939
18,842
20,512
18,633
17,854
17,175
17,274
16,844
16,335
16,161
17,270
103,850
32,234
31,174
30,172
29,611
28,346
26,192
25,505
24,780
24,080
23,578
22,925
22,257
21,664
21,025
20,311
19,689
19,195
18,586
18,171
17,496
16,891
16,225
15,523
14,875
14,130
14,13014,87515,52316,22516,89117,49618,17118,58619,19519,68920,31121,02521,66422,25722,92523,57824,08024,78025,50526,19228,34629,61130,17231,17432,234103,85017,27016,16116,33516,84417,27417,17517,85418,63320,51218,84217,93919,44621,07523,18325,01727,47729,82630,41533,56035,52437,37637,23135,01336,10037,53736,47034,85935,14033,62532,87533,48435,07434,36933,30029,11723,54022,55123,4030024,5964,146
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
649
649
785
785
785
785
785
785
785
785
785
785
785
785
785
0
0
0
785
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000007850007857857857857857857857857857857857857856496490000000000000000000000000000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
90,314
72,494
86,466
77,688
99,478
137,302
132,521
150,509
171,880
121,836
108,188
113,445
159,526
142,774
41,020
50,589
60,720
43,755
63,963
38,642
39,126
31,449
36,466
34,909
23,706
23,852
23,998
14,143
14,289
14,439
14,589
0
0
0
0
0
0
0
0
0
0
000000000014,58914,43914,28914,14323,99823,85223,70634,90936,46631,44939,12638,64263,96343,75560,72050,58941,020142,774159,526113,445108,188121,836171,880150,509132,521137,30299,47877,68886,46672,49490,314000000000000000000000000000
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
185,935
182,722
166,119
165,699
165,278
163,381
159,905
156,429
152,953
785
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,096
3,889
3,682
3,478
3,273
3,067
2,860
2,658
2,453
2,4532,6582,8603,0673,2733,4783,6823,8894,096000000000000000000785152,953156,429159,905163,381165,278165,699166,119182,722185,9350000000000000000000000000000000
       Long-term Assets Other 
0
8,041
0
0
8,448
8,452
8,192
10,808
7,900
7,921
7,898
7,861
7,839
7,785
7,771
7,721
7,701
7,930
13,359
13,238
12,786
12,458
12,042
11,744
11,672
13,957
14,175
101,965
84,464
97,841
88,178
109,543
146,961
142,224
158,349
179,675
129,692
116,114
121,310
168,603
151,158
47,560
57,071
61,717
44,746
64,939
40,451
40,917
32,815
37,109
924
25,070
25,192
25,483
15,583
15,646
15,787
15,921
1,305
4,430
3,823
3,608
3,398
4,257
6,285
5,923
5,538
5,151
5,1515,5385,9236,2854,2573,3983,6083,8234,4301,30515,92115,78715,64615,58325,48325,19225,07092437,10932,81540,91740,45164,93944,74661,71757,07147,560151,158168,603121,310116,114129,692179,675158,349142,224146,961109,54388,17897,84184,464101,96514,17513,95711,67211,74412,04212,45812,78613,23813,3597,9307,7017,7217,7717,7857,8397,8617,8987,9217,90010,8088,1928,4528,448008,0410
> Total Liabilities 
90,480
371,134
0
0
135,640
460,791
149,328
148,534
136,500
141,814
127,439
119,610
106,550
99,121
85,030
79,882
64,410
85,855
266,570
244,615
241,634
240,737
229,928
229,233
238,018
244,961
237,366
513,658
512,968
523,996
512,390
618,827
672,520
643,105
671,682
700,209
642,665
595,826
589,147
662,169
613,947
528,421
600,717
535,088
487,390
495,999
475,562
480,390
486,420
496,598
489,152
495,462
499,430
521,016
565,598
442,807
449,281
448,141
448,425
949,997
849,742
817,368
769,337
717,347
700,853
652,243
661,266
651,108
651,108661,266652,243700,853717,347769,337817,368849,742949,997448,425448,141449,281442,807565,598521,016499,430495,462489,152496,598486,420480,390475,562495,999487,390535,088600,717528,421613,947662,169589,147595,826642,665700,209671,682643,105672,520618,827512,390523,996512,968513,658237,366244,961238,018229,233229,928240,737241,634244,615266,57085,85564,41079,88285,03099,121106,550119,610127,439141,814136,500148,534149,328460,791135,64000371,13490,480
   > Total Current Liabilities 
29,931
39,152
0
0
51,139
56,437
54,984
57,201
55,800
64,426
60,532
70,844
70,848
65,134
52,283
49,121
35,577
54,938
62,682
43,966
39,701
41,040
38,500
41,626
54,057
60,541
59,813
62,099
67,780
76,465
78,113
90,999
95,305
91,131
78,893
79,973
64,489
66,027
62,336
94,984
112,582
119,524
118,569
110,861
52,795
40,929
27,595
26,695
32,901
32,713
23,603
134,370
145,694
161,698
147,403
23,298
27,117
25,525
23,843
305,390
280,579
276,101
252,442
45,510
49,383
38,846
48,097
232,525
232,52548,09738,84649,38345,510252,442276,101280,579305,39023,84325,52527,11723,298147,403161,698145,694134,37023,60332,71332,90126,69527,59540,92952,795110,861118,569119,524112,58294,98462,33666,02764,48979,97378,89391,13195,30590,99978,11376,46567,78062,09959,81360,54154,05741,62638,50041,04039,70143,96662,68254,93835,57749,12152,28365,13470,84870,84460,53264,42655,80057,20154,98456,43751,1390039,15229,931
       Short-term Debt 
0
1,060
0
0
1,554
1,079
1,460
1,263
227
197
241
229
228
233
271
277
280
261
242
223
1,115
1,139
5,537
7,681
10,475
12,410
14,384
18,774
22,446
27,595
30,689
37,710
15,455
6,227
11,002
10,194
8,822
8,154
15,317
27,326
39,362
47,627
58,041
60,701
19,868
1,146
3,752
5,220
6,224
3,128
6,288
116,013
117,989
119,985
123,678
6,132
6,100
3,065
6,160
202,178
202,432
202,686
202,942
6,314
6,346
6,378
6,408
205,772
205,7726,4086,3786,3466,314202,942202,686202,432202,1786,1603,0656,1006,132123,678119,985117,989116,0136,2883,1286,2245,2203,7521,14619,86860,70158,04147,62739,36227,32615,3178,1548,82210,19411,0026,22715,45537,71030,68927,59522,44618,77414,38412,41010,4757,6815,5371,1391,1152232422612802772712332282292411972271,2631,4601,0791,554001,0600
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
11,258
0
0
0
24,964
30,689
37,710
11,930
372,801
5,501
392,957
396,340
400,168
11,958
24,861
39,191
47,554
45,961
48,797
0
0
0
0
0
0
0
112,852
114,832
116,858
120,581
0
0
0
0
199,083
199,321
199,560
199,800
0
0
0
0
199,332
199,3320000199,800199,560199,321199,0830000120,581116,858114,832112,852000000048,79745,96147,55439,19124,86111,958400,168396,340392,9575,501372,80111,93037,71030,68924,96400011,2580000000000000000000000000
       Accounts payable 
5,585
3,734
0
0
6,434
4,754
5,116
5,202
5,900
4,302
2,918
6,507
2,390
6,436
3,171
10,626
4,793
21,726
29,744
13,837
8,225
10,187
4,862
3,398
6,109
9,762
5,227
6,650
5,904
8,589
4,741
8,999
19,752
17,703
20,578
21,190
17,514
15,958
11,609
23,786
9,332
14,891
11,203
9,908
6,098
5,487
3,839
2,855
2,372
661
842
466
414
935
532
317
795
483
118
3,505
4,698
7,830
6,222
3,227
3,236
2,127
5,827
1,389
1,3895,8272,1273,2363,2276,2227,8304,6983,5051184837953175329354144668426612,3722,8553,8395,4876,0989,90811,20314,8919,33223,78611,60915,95817,51421,19020,57817,70319,7528,9994,7418,5895,9046,6505,2279,7626,1093,3984,86210,1878,22513,83729,74421,7264,79310,6263,1716,4362,3906,5072,9184,3025,9005,2025,1164,7546,434003,7345,585
       Other Current Liabilities 
23,340
18,698
0
0
10,241
18,244
12,850
14,096
14,183
19,877
14,446
15,553
20,583
22,174
23,906
24,640
27,374
29,570
29,397
24,832
25,287
24,640
21,973
24,100
32,399
31,178
33,011
29,484
32,239
33,090
33,374
35,771
55,971
67,201
46,572
48,364
38,153
41,915
35,410
43,872
50,367
57,006
49,325
40,252
25,551
33,421
19,129
17,745
22,041
28,384
16,173
17,891
26,791
40,578
22,893
16,649
20,222
21,321
14,865
93,061
72,175
63,097
39,478
35,034
38,815
27,788
33,345
25,364
25,36433,34527,78838,81535,03439,47863,09772,17593,06114,86521,32120,22216,64922,89340,57826,79117,89116,17328,38422,04117,74519,12933,42125,55140,25249,32557,00650,36743,87235,41041,91538,15348,36446,57267,20155,97135,77133,37433,09032,23929,48433,01131,17832,39924,10021,97324,64025,28724,83229,39729,57027,37424,64023,90622,17420,58315,55314,44619,87714,18314,09612,85018,24410,2410018,69823,340
   > Long-term Liabilities 
0
331,982
0
0
84,501
404,354
94,344
91,333
80,700
77,388
66,907
48,766
35,702
33,987
32,747
30,761
28,833
30,917
203,888
200,649
201,933
199,697
191,428
187,607
183,961
184,420
177,553
451,559
445,188
447,531
434,277
527,828
577,215
551,974
592,789
620,236
578,176
529,799
526,811
567,185
501,365
408,897
482,148
424,227
434,595
455,070
447,967
453,695
453,519
463,885
465,549
361,092
353,736
359,318
418,195
419,509
422,164
422,616
424,582
644,607
569,163
541,267
516,895
671,837
651,470
613,397
613,169
418,583
418,583613,169613,397651,470671,837516,895541,267569,163644,607424,582422,616422,164419,509418,195359,318353,736361,092465,549463,885453,519453,695447,967455,070434,595424,227482,148408,897501,365567,185526,811529,799578,176620,236592,789551,974577,215527,828434,277447,531445,188451,559177,553184,420183,961187,607191,428199,697201,933200,649203,88830,91728,83330,76132,74733,98735,70248,76666,90777,38880,70091,33394,344404,35484,50100331,9820
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
540
481
422
435
364
361
308
174,855
174,826
178,077
177,806
173,154
171,297
168,260
164,909
160,427
364,044
360,257
353,890
348,833
339,409
362,802
366,574
383,909
387,860
391,929
396,091
388,373
379,820
369,944
366,296
360,087
352,725
402,675
407,994
413,409
418,924
424,539
430,256
436,078
329,155
333,212
337,333
395,053
395,451
395,850
396,251
396,653
597,974
0
0
0
0
0
0
0
0
00000000597,974396,653396,251395,850395,451395,053337,333333,212329,155436,078430,256424,539418,924413,409407,994402,675352,725360,087366,296369,944379,820388,373396,091391,929387,860383,909366,574362,802339,409348,833353,890360,257364,044160,427164,909168,260171,297173,154177,806178,077174,826174,85530836136443542248154000000000000
       Capital Lease Obligations Min Short Term Debt
0
-1,060
0
0
-1,554
-1,079
-1,460
-1,263
-227
-197
-241
311
253
189
164
87
81
47
12
-25
2,312
1,995
-2,695
-4,523
-7,607
-9,839
-12,116
-16,815
-21,378
-27,289
-30,436
-37,512
-15,314
-6,145
-10,981
-10,194
-8,822
-8,154
-15,317
-27,326
-39,362
-47,469
33,989
-30,112
12,726
22,082
19,770
18,601
17,655
20,318
16,718
-93,458
-95,902
-98,374
-102,550
14,501
14,037
16,599
13,025
-183,485
-184,247
-185,017
-185,796
10,295
9,709
9,115
8,513
-191,435
-191,4358,5139,1159,70910,295-185,796-185,017-184,247-183,48513,02516,59914,03714,501-102,550-98,374-95,902-93,45816,71820,31817,65518,60119,77022,08212,726-30,11233,989-47,469-39,362-27,326-15,317-8,154-8,822-10,194-10,981-6,145-15,314-37,512-30,436-27,289-21,378-16,815-12,116-9,839-7,607-4,523-2,6951,9952,312-2512478187164189253311-241-197-227-1,263-1,460-1,079-1,55400-1,0600
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
0
0
0
703
0
0
0
0
0
992
909
1,653
1,653
1,653
0
0
0
0
0
3,845
10,645
10,120
10,120
97,172
91,802
71,606
72,902
79,403
78,020
36,071
36,449
38,288
2,530
2,530
2,723
2,626
492
734
705
602
518
1,763
1,630
1,482
1,594
3,501
5,111
6,491
9,227
9,766
11,824
31,035
30,948
28,415
29,414
34,738
39,771
17,105
17,292
22,466
22,46617,29217,10539,77134,73829,41428,41530,94831,03511,8249,7669,2276,4915,1113,5011,5941,4821,6301,7635186027057344922,6262,7232,5302,53038,28836,44936,07178,02079,40372,90271,60691,80297,17210,12010,12010,6453,845000001,6531,6531,6539099920000070300000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
47,523
35,221
33,565
32,312
30,397
28,472
29,617
28,124
24,170
22,203
20,238
18,274
16,310
15,701
19,511
17,126
83,670
74,286
83,521
75,324
91,247
122,611
113,794
135,978
152,973
108,227
97,637
101,989
149,077
128,891
40,071
39,388
50,191
8,768
24,260
12,207
12,958
7,695
12,088
7,979
11,061
0
0
0
0
0
0
0
2,800
0
0
0
0
0
0
0
0
000000002,800000000011,0617,97912,0887,69512,95812,20724,2608,76850,19139,38840,071128,891149,077101,98997,637108,227152,973135,978113,794122,61191,24775,32483,52174,28683,67017,12619,51115,70116,31018,27420,23822,20324,17028,12429,61728,47230,39732,31233,56535,22147,52300000000000
> Total Stockholder Equity
38,933
-235,750
0
0
19,351
-301,552
188,802
170,740
168,100
159,551
144,585
130,117
112,930
109,856
164,146
128,781
182,108
144,052
58,523
139,416
84,209
38,225
188,943
141,831
108,150
88,552
68,162
140,283
100,458
95,125
90,935
81,381
59,458
66,716
29,637
4,870
-17,579
9,848
-18,052
-43,951
-197,295
-196,371
-237,179
-219,367
-153,047
-93,251
-71,557
-36,852
5,904
62,640
110,192
511,756
579,941
605,911
517,783
532,883
591,063
652,378
706,852
-345,704
-323,216
-346,295
-330,518
-321,727
-311,334
-301,335
-334,053
-308,162
-308,162-334,053-301,335-311,334-321,727-330,518-346,295-323,216-345,704706,852652,378591,063532,883517,783605,911579,941511,756110,19262,6405,904-36,852-71,557-93,251-153,047-219,367-237,179-196,371-197,295-43,951-18,0529,848-17,5794,87029,63766,71659,45881,38190,93595,125100,458140,28368,16288,552108,150141,831188,94338,22584,209139,41658,523144,052182,108128,781164,146109,856112,930130,117144,585159,551168,100170,740188,802-301,55219,35100-235,75038,933
   Common Stock
7
7
0
0
78
8
98
98
100
99
100
100
101
101
107
108
108
108
109
121
121
121
138
138
140
141
142
142
143
143
144
145
146
148
149
150
149
151
152
153
154
154
156
156
157
158
159
160
160
161
162
163
163
162
155
153
153
154
155
156
156
156
159
160
160
160
162
162
1621621601601601591561561561551541531531551621631631621611601601591581571561561541541531521511491501491481461451441431431421421411401381381211211211091081081081071011011001009910098988780077
   Retained Earnings Total Equity00000000-1,712,849-650,662-696,376-745,243-795,560-832,640-937,608-978,982-1,034,827-1,426,130-1,466,056-1,509,260-1,543,683-1,568,887-1,572,232-1,620,090-1,640,738-1,650,412-1,591,128-1,575,635-1,401,284-1,351,904-1,308,760-1,320,845-1,288,548-1,244,324-1,191,823-1,178,318-1,145,114-1,123,412-1,110,115-1,096,078-1,048,688-1,000,668-967,446-929,799-887,811-827,454-777,828-725,842-664,067-598,918-505,016-461,161-508,796-467,993-432,392-425,418-404,78500000000000
   Accumulated Other Comprehensive Income 
0
23
0
0
2
-298,350
-99
44
48
1
52
53
6
6
3
-9
7
5
12
-1
19
2
-12
3
25
-19
3
22
48
-86
29
39
61
-7
-41
-24
-6
-79
-91
-44
-9
0
0
0
0
-10,082
0
0
0
-11,805
1,536,322
0
0
0
0
0
0
0
0
0
-752
-3,031
-922
-470
-2,052
923
294
-2,026
-2,026294923-2,052-470-922-3,031-7520000000001,536,322-11,805000-10,0820000-9-44-91-79-6-24-41-7613929-8648223-19253-12219-11257-9366535214844-99-298,350200230
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
534,749
538,241
542,141
632,029
637,478
643,154
648,955
657,320
803,363
809,911
815,930
1,016,271
1,029,501
1,037,784
1,055,876
1,068,685
1,188,807
1,196,345
1,205,183
1,214,174
1,226,311
1,237,569
1,258,398
1,273,853
1,293,292
1,303,123
1,318,536
1,333,791
1,357,224
1,378,195
1,394,603
1,413,077
1,421,215
1,466,886
1,478,823
1,497,171
1,506,671
1,515,004
1,528,535
1,536,160
1,546,420
1,558,760
1,543,357
1,350,268
1,328,290
1,336,153
1,348,600
1,357,359
1,366,989
0
0
0
0
0
0
0
0
000000001,366,9891,357,3591,348,6001,336,1531,328,2901,350,2681,543,3571,558,7601,546,4201,536,1601,528,5351,515,0041,506,6711,497,1711,478,8231,466,8861,421,2151,413,0771,394,6031,378,1951,357,2241,333,7911,318,5361,303,1231,293,2921,273,8531,258,3981,237,5691,226,3111,214,1741,205,1831,196,3451,188,8071,068,6851,055,8761,037,7841,029,5011,016,271815,930809,911803,363657,320648,955643,154637,478632,029542,141538,241534,74900000000000
   Treasury Stock00000000000000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
7,594
0
0
309,307
311,349
516,403
518,217
523,852
526,991
530,374
534,749
538,241
542,141
632,029
637,478
643,154
648,955
657,320
803,363
809,911
815,930
1,016,271
1,029,501
1,037,784
1,055,876
1,068,685
1,188,807
1,196,345
1,205,183
1,214,174
1,226,311
1,237,569
1,258,398
1,273,853
1,293,292
1,303,123
1,318,536
1,333,791
1,357,224
1,378,195
1,394,603
1,413,077
1,421,215
1,466,886
1,488,905
1,497,171
1,506,671
1,515,004
1,528,535
1,536,160
1,546,420
1,558,760
1,543,357
1,350,268
1,328,290
1,336,153
1,348,600
1,357,359
1,366,989
1,374,908
1,355,195
1,373,022
1,382,220
1,390,549
1,395,317
1,400,612
1,405,224
1,405,2241,400,6121,395,3171,390,5491,382,2201,373,0221,355,1951,374,9081,366,9891,357,3591,348,6001,336,1531,328,2901,350,2681,543,3571,558,7601,546,4201,536,1601,528,5351,515,0041,506,6711,497,1711,488,9051,466,8861,421,2151,413,0771,394,6031,378,1951,357,2241,333,7911,318,5361,303,1231,293,2921,273,8531,258,3981,237,5691,226,3111,214,1741,205,1831,196,3451,188,8071,068,6851,055,8761,037,7841,029,5011,016,271815,930809,911803,363657,320648,955643,154637,478632,029542,141538,241534,749530,374526,991523,852518,217516,403311,349309,307007,5940



5.4. Balance Sheets

Currency in USD. All numbers in thousands.




5.5. Cash Flows

Currency in USD. All numbers in thousands.




5.6. Income Statements

Currency in USD. All numbers in thousands.


5.7. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue351,410
Cost of Revenue-2,011
Gross Profit343,858349,399
 
Operating Income (+$)
Gross Profit343,858
Operating Expense-250,734
Operating Income93,12493,124
 
Operating Expense (+$)
Research Development111,421
Selling General Administrative144,272
Selling And Marketing Expenses0
Operating Expense250,734255,693
 
Net Interest Income (+$)
Interest Income4,468
Interest Expense-33,034
Other Finance Cost-0
Net Interest Income-28,566
 
Pretax Income (+$)
Operating Income93,124
Net Interest Income-28,566
Other Non-Operating Income Expenses0
Income Before Tax (EBT)65,198121,050
EBIT - interestExpense = 65,198
65,198
33,914
Interest Expense33,034
Earnings Before Interest and Taxes (EBIT)98,23298,232
Earnings Before Interest and Taxes (EBITDA)100,243
 
After tax Income (+$)
Income Before Tax65,198
Tax Provision-64,318
Net Income From Continuing Ops880880
Net Income880
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses258,286
Total Other Income/Expenses Net-27,92628,566
 

Technical Analysis of Ironwood Pharmaceuticals Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Ironwood Pharmaceuticals Inc. The general trend of Ironwood Pharmaceuticals Inc is BULLISH with 71.4% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Ironwood Pharmaceuticals Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (71.4%) Bearish trend (-71.4%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Ironwood Pharmaceuticals Inc Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

SupportΒ is a price level at which demand for an asset is strong enough to prevent the price from falling further.
ResistanceΒ is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Ironwood Pharmaceuticals Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 2.12 < 3.06 < 3.369.

The bearish price targets are: 1.4705 > 1.41 > 1.26.

Know someone who trades $IRWD? Share this with them.πŸ‘‡

Ironwood Pharmaceuticals Inc Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows theΒ moving averageΒ of the selected period.

  • Moving averages are laggingΒ trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Ironwood Pharmaceuticals Inc. The current mas is .

The long score for the Moving Averages is 12/14.
The longshort score for the Moving Averages is 10/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Ironwood Pharmaceuticals Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows theΒ momentumΒ of theΒ selected period based on two moving averages.

  • MACD is aΒ lagging momentumΒ indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Ironwood Pharmaceuticals Inc. The current macd is 0.137384.

The long score for the Moving Average Convergence/Divergence (MACD) is 4/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 4/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Ironwood Pharmaceuticals Inc price going up in the near term. +2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Ironwood Pharmaceuticals Inc. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Ironwood Pharmaceuticals Inc price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Ironwood Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) ChartIronwood Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Ironwood Pharmaceuticals Inc. The current adx is 45.78.

The long score for the Directional Movement Index (DMI) is 4/7.
The longshort score for the Directional Movement Index (DMI) is 4/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Ironwood Pharmaceuticals Inc shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bullish trend. The ADX is trending up, so the bullish trend is strengthening.
Ironwood Pharmaceuticals Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • ShowsΒ the current trend.
  • ShowsΒ potential entry signals.
  • ShowsΒ Β potential exit signals.
  • Can be used to placeΒ trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Ironwood Pharmaceuticals Inc. The current sar is 1.56187908.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Ironwood Pharmaceuticals Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentumΒ indicator, meaning the signals are instant.
  • RangesΒ between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Ironwood Pharmaceuticals Inc. The current rsi is 61.40. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 3/13.
The longshort score for the Relative Strength Index (RSI) is 2/(-13 +13).

  • Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
  • Trending down: The RSI is trending down. -1
Ironwood Pharmaceuticals Inc Daily Relative Strength Index (RSI) ChartIronwood Pharmaceuticals Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

ComparesΒ a certain price to multiple prices ranging over time.

  • LeadingΒ momentumΒ indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • RangesΒ between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Ironwood Pharmaceuticals Inc. The current phase is Continuation in bull market.

The long score for the Stochastic Oscillator is 1/6.
The longshort score for the Stochastic Oscillator is -2/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Ironwood Pharmaceuticals Inc price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Ironwood Pharmaceuticals Inc Daily Stochastic Oscillator ChartIronwood Pharmaceuticals Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero,Β the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Ironwood Pharmaceuticals Inc. The current cci is 117.96.

The long score for the Commodity Channel Index (CCI) is 1/1.
The longshort score for the Commodity Channel Index (CCI) is 1/(-1 +1).

  • CCI > 100: The CCI is above 100, it indicates that the price is significantly above its average, suggesting a potential overbought condition. +1
Ironwood Pharmaceuticals Inc Daily Commodity Channel Index (CCI) ChartIronwood Pharmaceuticals Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Ironwood Pharmaceuticals Inc. The current cmo is 23.26.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Ironwood Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) ChartIronwood Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

Β Shows the current price relative to the highest high over the last 14 days.
Β 

  • Lagging momentum indicator
  • Ranging between 0 andΒ -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Ironwood Pharmaceuticals Inc. The current willr is -40.81632653.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Ironwood Pharmaceuticals Inc is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Ironwood Pharmaceuticals Inc Daily Williams %R ChartIronwood Pharmaceuticals Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversoldΒ 

Score

Let's take a look at the Bollinger Bands of Ironwood Pharmaceuticals Inc.

Ironwood Pharmaceuticals Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Ironwood Pharmaceuticals Inc. The current atr is 0.17408727.

Ironwood Pharmaceuticals Inc Daily Average True Range (ATR) ChartIronwood Pharmaceuticals Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

Β Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Ironwood Pharmaceuticals Inc. The current obv is -109,542,654.

Ironwood Pharmaceuticals Inc Daily On-Balance Volume (OBV) ChartIronwood Pharmaceuticals Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Ironwood Pharmaceuticals Inc. The current mfi is 67.31.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Ironwood Pharmaceuticals Inc Daily Money Flow Index (MFI) ChartIronwood Pharmaceuticals Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Ironwood Pharmaceuticals Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-06-20CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-06-23STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-24STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-25CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-06-27STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-02STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-03WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-07-07STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-08STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-07-09CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-07-10STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-15MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-07-16DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-07-17MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-07-21STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-22STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-07-23SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-07-24STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-29STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-07-30STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-31CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-08-01MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-08-04SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-08-05STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-08-07MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-08-11STOCH LONG EXITThe %K line crosses below the %D line.
2025-08-12STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-08-13WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-08-15STOCH LONG EXITThe %K line crosses below the %D line.
2025-08-18STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-08-19STOCH LONG EXITThe %K line crosses below the %D line.
2025-08-20WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-08-22STOCH LONG EXITThe %K line crosses below the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-08-28STOCH SHORT EXITThe %K line crosses above the %D line.
2025-09-02STOCH LONG EXITThe %K line crosses below the %D line.
2025-09-03RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2025-09-04MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-09-08STOCH SHORT EXITThe %K line crosses above the %D line.
2025-09-09STOCH LONG EXITThe %K line crosses below the %D line.
2025-09-10STOCH SHORT EXITThe %K line crosses above the %D line.
2025-09-11CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-09-12WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-09-16SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-09-17STOCH LONG EXITThe %K line crosses below the %D line.
2025-09-18MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-09-23STOCH LONG EXITThe %K line crosses below the %D line.
2025-09-24MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-09-25MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-09-26STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-09-30STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-10-01STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-10-02MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-10-03STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-10-07STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-10-08CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-10-09WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-10-10STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-10-13SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-10-14MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-10-15STOCH SHORT EXITThe %K line crosses above the %D line.
2025-10-16STOCH LONG EXITThe %K line crosses below the %D line.
2025-10-17CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-10-20STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-10-21STOCH LONG EXITThe %K line crosses below the %D line.
2025-10-23STOCH SHORT EXITThe %K line crosses above the %D line.
2025-10-24CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-10-27STOCH LONG EXITThe %K line crosses below the %D line.
2025-10-28CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-10-29WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-10-30STOCH SHORT EXITThe %K line crosses above the %D line.
2025-10-31MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-11-04STOCH LONG EXITThe %K line crosses below the %D line.
2025-11-05STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-11-07STOCH LONG EXITThe %K line crosses below the %D line.

6.3. Candlestick Patterns

Ironwood Pharmaceuticals Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Ironwood Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5061.401
Ma 20Greater thanMa 501.669
Ma 50Greater thanMa 1001.486
Ma 100Greater thanMa 2001.179
OpenGreater thanClose2.060
Total4/5 (80.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Ironwood Pharmaceuticals Inc with someone you think should read this too:
  • Are you bullish or bearish on Ironwood Pharmaceuticals Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Ironwood Pharmaceuticals Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Ironwood Pharmaceuticals Inc

I send you an email if I find something interesting about Ironwood Pharmaceuticals Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Ironwood Pharmaceuticals Inc.

Receive notifications about Ironwood Pharmaceuticals Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.